<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000769613"><TermName>Lenvima</TermName><TermPronunciation>(len-VEE-muh)</TermPronunciation><TermDefinition><DefinitionText>A drug used to treat thyroid cancer in certain patients with progressive, recurrent, or metastatic disease that does not respond to treatment with radioactive iodine. It is also being studied in the treatment of other types of cancer. Lenvima blocks certain proteins needed for cells to grow and may kill cancer cells. It is a type of tyrosine kinase inhibitor. Also called lenvatinib mesylate.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000771228" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Lenvima&quot;" language="en" id="_3"/><MediaLink ref="CDR0000771227" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Lenvima&quot;" language="es" id="_4"/><SpanishTermName>Lenvima</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para tratar a ciertos pacientes de cáncer de tiroides con enfermedad evolutiva, recidivante o metastásica que no responde al tratamiento con yodo radiactivo. También está en estudio para el tratamiento de otros tipos de cáncer. Lenvima bloquea ciertas proteínas que las células necesitan para crecer y puede destruir células cancerosas. Es un tipo de inhibidor de la tirosina cinasa. También se llama mesilato de lenvatinib.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2015-02-26</DateFirstPublished><RelatedInformation><RelatedDrugSummaryRef href="CDR0000769403">Lenvatinib Mesylate</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
